Literature DB >> 8918422

Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome.

D S Sheth1, A W Yasko, A K Raymond, A G Ayala, C H Carrasco, R S Benjamin, N Jaffe, J A Murray.   

Abstract

BACKGROUND: Dedifferentiated parosteal osteosarcoma (dd-POS) designates high grade transformation, of conventional low grade parosteal osteosarcoma (c-POS). The paradigm of preoperative diagnosis, neoadjuvant chemotherapy, and wide local excision has not been adequately evaluated for dd-POS, as it has been for conventional high grade intramedullary osteosarcoma.
METHODS: A retrospective review was conducted of 28 patients treated at the authors' institution between January 1980 and December 1992 for an osteosarcoma arising on the surface of the bone diagnosed as either c-POS or dd-POS. The clinicopathologic features, diagnosis, treatment, and patient outcome were analyzed.
RESULTS: A dedifferentiated component was identified in 12 of 28 tumors (43%). Neither the presence of radiolucencies (77% in c-POS and 100% in dd-POS, P = 0.06) nor medullary invasion (42% in c-POS and 50% in dd-POS, P = 0.28) distinguished dd-POS from c-POS. However, all patients who presented with focal hypervascularity on an arteriogram defined the high grade component of dd-POS that was confirmed by selective needle biopsy. This differed significantly (P = 0.00003) from c-POS. None of the patients with c-POS died of the disease (median survival duration, 77 months; range, 16-152 months). Six patients (35%) developed a local recurrence, but five were treated successfully with further surgery. In the dd-POS group, 7 of the 12 patients died of the disease. Ten patients with dd-POS received preoperative chemotherapy (IA cis-diamminedichloroplatinum, IV doxorubicin), and a good response (> 90% necrosis of high grade component) was observed in four. Among patients whose disease was localized, continuous disease free survival was prolonged significantly (P = 0.03) in patients with a good response (median, 75 months) compared with those who responded poorly (median, 13 months). Five patients remained continuously disease free (median, 66 months, range, 29-95 months).
CONCLUSIONS: Wide surgical excision alone is adequate treatment for patients with c-POS. Recognition of dedifferentiated areas with angiography and percutaneous biopsy of hypervascular areas should prompt the administration of chemotherapy and wide local excision to optimize patient outcome.

Entities:  

Mesh:

Year:  1996        PMID: 8918422

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Dedifferentiated parosteal osteosarcoma of the calvaria.

Authors:  Rajiv Mangla; Manisha Mangla; Shuo Li; Ahmed Abdelbaki; Itisha Bansal; Anil Kumar; Yogesh Kumar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-01-03

2.  Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging.

Authors:  M Azura; D Vanel; M Alberghini; P Picci; E Staals; M Mercuri
Journal:  Skeletal Radiol       Date:  2009-03-07       Impact factor: 2.199

3.  A case of dedifferentiated solitary fibrous tumor of the thoracic cavity.

Authors:  Yoshio Masuda; Aiko Kurisaki-Arakawa; Kieko Hara; Atsushi Arakawa; Shiaki Oh; Kenji Suzuki; Takashi Yao; Tsuyoshi Saito
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

4.  A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma.

Authors:  Joseph H Schwab; Cristina R Antonescu; Edward A Athanasian; Patrick J Boland; John H Healey; Carol D Morris
Journal:  Clin Orthop Relat Res       Date:  2008-04-19       Impact factor: 4.176

5.  Dedifferentiated parosteal osteosarcoma with well-differentiated metastases.

Authors:  Katsuhito Takeuchi; Takeshi Morii; Hiroo Yabe; Hideo Morioka; Makio Mukai; Yoshiaki Toyama
Journal:  Skeletal Radiol       Date:  2006-03-01       Impact factor: 2.199

6.  GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.

Authors:  Carolina Salinas-Souza; Carlos De Andrea; Michel Bihl; Michal Kovac; Nischalan Pillay; Tim Forshew; Alice Gutteridge; Hongtao Ye; M Fernanda Amary; Roberto Tirabosco; Silvia Regina Caminada Toledo; Daniel Baumhoer; Adrienne M Flanagan
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

Review 7.  Common musculoskeletal tumors of childhood and adolescence.

Authors:  Carola A S Arndt; Peter S Rose; Andrew L Folpe; Nadia N Laack
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

8.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

9.  Dedifferentiated parosteal osteosarcoma with giant cell tumor component.

Authors:  Diana M Cardona; Jacquelyn A Knapik; John D Reith
Journal:  Skeletal Radiol       Date:  2008-02-07       Impact factor: 2.199

10.  Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009.

Authors:  Kjetil Berner; Tom Børge Johannesen; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.